Astrazeneca Pharma India Ltd

ASTRAZEN

Watchlist

AI Mode

‌

Market Cap

₹ 22,811 Cr

P/E

98.68

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

MARKET LEADER

Valuation

OVERVALUED

Growth

STABLE

Profitability

HIGH MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

AstraZeneca Pharma India Limited (APIL) is a subsidiary engaged in manufacturing, distributing, and marketing pharmaceutical products, focusing on therapeutic areas like oncology, cardio metabolic, and respiratory care.

The company has aligned with AstraZeneca PLC’s global therapeutic focus, driving significant market presence in India’s diabetes and cardiovascular segments through strategic partnerships and product launches.

APIL's recent launch of innovative drugs like Transtuzumab Deruxtecan for breast cancer marks its significant entry into advanced oncology treatment.

While regulatory interventions have influenced drug pricing, strategic responses like partnerships with Dr. Reddy's Laboratories and Sun Pharma enhanced APIL’s market access and portfolio reach.

APIL continues its R&D expansion in Bangalore, reinforcing its role within AstraZeneca’s global research network.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Multinational

Market Cap

22,811 Cr

Volatility

Low Risk

P/E Ratio

98.7

Industry P/E

41.4

PEG Ratio

4.2

P/B Ratio

28.6

52W High

10,653.05

52W Low

6,301.00

Sales CAGR

32.48%

28.67%

15.59%

10Y

13.03%

Profit CAGR

-28.34%

23.40%

9.89%

10Y

40.99%

ROE

TTM

28.93%

18.18%

17.49%

10Y

16.38%

ROCE

TTM

37.48%

24.02%

23.16%

10Y

22.37%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ABBOTINDIA	27900.00	59,278 Cr	39.28	14.78	1.70	37.62	48.38	26.50
GLAXO	2575.00	43,623 Cr	45.76	25.54	2.10	55.94	74.64	26.06
PFIZER	5034.00	22,933 Cr	32.45	5.96	3.29	18.36	24.12	18.22
ASTRAZEN	9137.50	22,811 Cr	98.68	28.55	0.35	28.93	37.48	12.33
SANOFICONR	4570.00	10,559 Cr	49.14	41.08	1.20	77.82	92.58	51.64
SANOFI	4204.00	9,666 Cr	25.45	11.23	2.78	42.11	52.41	25.64
PGHL	5663.25	9,422 Cr	30.71	15.20	2.20	49.51	65.17	34.30

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	295	311	306	383	388	408	440	480	526	559
Expenses	228	258	291	334	349	355	363	394	445	484
Operating Profit	67	53	15	49	38	53	77	86	81	75
OPM %	22.76	16.96	4.92	12.89	9.82	12.88	17.49	17.98	15.41	13.45
Other Income	8.10	25	9.66	8.66	-49	8.15	-26	10	11	0.88
Interest	0.15	0.50	0.61	-0.07	0.11	0.34	0.33	0.68	0.72	0.67
Depreciation	3.79	3.68	3.70	3.76	3.91	9.32	9.07	18	17	2.57
Profit Before Tax	71	73	20	54	-15	51	42	78	75	73
Tax %	24.57	28.63	22.55	27.37	22.23	24.69	26.58	25.77	25.26	25.54
Net Profit	54	52	16	39	-12	38	31	58	56	54
EPS in Rs	21.54	20.95	6.32	15.79	-4.72	16.37	12.34	23.30	22.33	21.69

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	549	572	728	832	814	806	1,003	1,296	1,716	1,855
Expenses	507	525	657	711	678	719	838	1,111	1,462	1,558
Operating Profit	42	47	71	121	135	86	165	184	254	297
OPM %	7.63	8.27	9.79	14.51	16.65	10.70	16.46	14.24	14.80	16.01
Other Income	14	12	16	13	13	15	-14	51	-56	3.93
Interest	0.00	0.00	0.00	1.14	1.09	0.95	0.63	1.20	1.46	2.07
Depreciation	16	15	15	19	20	17	16	15	40	53
Profit Before Tax	36	44	73	114	127	83	134	220	156	246
Tax %	43.52	40.84	25.07	36.64	26.59	25.82	25.96	26.43	25.98	25.53
Net Profit	20	26	54	72	93	62	99	162	116	183
EPS in Rs	8.02	10.42	21.80	28.89	37.32	24.64	39.72	64.60	47.29	79.66
Dividend Payout %	0.00	0.00	0.00	3.46	5.36	40.65	40.30	37.15	69.11	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Reserves	151	218	242	296	359	451	506	584	707	765
Borrowings	0.00	0.00	0.00	0.00	12	12	8.63	7.21	4.59	36
Other Liabilities	247	193	214	261	330	306	337	389	362	712
Total Liabilities	403	415	461	562	706	775	857	985	1,078	1,518
Fixed Assets	97	87	75	75	72	81	74	69	67	64
CWIP	6.31	4.81	3.57	6.90	24	4.02	2.20	1.33	0.27	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	299	324	382	480	611	690	780	915	1,011	1,454
Total Assets	403	415	461	562	706	775	857	985	1,078	1,518

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	57	38	8.79	55	87	105	101	58	28	65
Cash from Investing Activity	-3.61	0.25	-9.36	4.28	-171	173	4.74	18	22	31
Cash from Financing Activity	-0.51	0.00	0.00	0.00	-6.36	-8.97	-9.46	-24	-44	-66
Net Cash Flow	53	38	-0.57	59	-90	269	96	52	5.23	31

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
FIIs	2.61%	2.70%	2.68%	2.69%	2.65%	2.74%	2.79%	2.90%	2.93%	2.89%	3.03%	2.74%
DIIs	1.44%	1.42%	1.93%	2.43%	2.78%	3.78%	5.01%	5.10%	5.22%	4.65%	4.56%	5.26%
Public	20.96%	20.88%	20.40%	19.88%	19.57%	18.48%	17.20%	17.00%	16.85%	17.46%	17.41%	17.00%
Total Shareholders	45,619	42,146	38,946	32,380	29,032	29,418	27,169	27,615	27,322	32,466	34,378	32,914

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q1 FY24

Investor Presentation

Q1 FY23

Investor Presentation

Q1 FY22

Investor Presentation

Q1 FY21

Investor Presentation

Q1 FY19

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	295	311	306	383	388	408	440	480	526	559
Expenses	228	258	291	334	349	355	363	394	445	484
Operating Profit	67	53	15	49	38	53	77	86	81	75
OPM %	22.76	16.96	4.92	12.89	9.82	12.88	17.49	17.98	15.41	13.45
Other Income	8.10	25	9.66	8.66	-49	8.15	-26	10	11	0.88
Interest	0.15	0.50	0.61	-0.07	0.11	0.34	0.33	0.68	0.72	0.67
Depreciation	3.79	3.68	3.70	3.76	3.91	9.32	9.07	18	17	2.57
Profit Before Tax	71	73	20	54	-15	51	42	78	75	73
Tax %	24.57	28.63	22.55	27.37	22.23	24.69	26.58	25.77	25.26	25.54
Net Profit	54	52	16	39	-12	38	31	58	56	54
EPS in Rs	21.54	20.95	6.32	15.79	-4.72	16.37	12.34	23.30	22.33	21.69

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	549	572	728	832	814	806	1,003	1,296	1,716	1,855
Expenses	507	525	657	711	678	719	838	1,111	1,462	1,558
Operating Profit	42	47	71	121	135	86	165	184	254	297
OPM %	7.63	8.27	9.79	14.51	16.65	10.70	16.46	14.24	14.80	16.01
Other Income	14	12	16	13	13	15	-14	51	-56	3.93
Interest	0.00	0.00	0.00	1.14	1.09	0.95	0.63	1.20	1.46	2.07
Depreciation	16	15	15	19	20	17	16	15	40	53
Profit Before Tax	36	44	73	114	127	83	134	220	156	246
Tax %	43.52	40.84	25.07	36.64	26.59	25.82	25.96	26.43	25.98	25.53
Net Profit	20	26	54	72	93	62	99	162	116	183
EPS in Rs	8.02	10.42	21.80	28.89	37.32	24.64	39.72	64.60	47.29	79.66
Dividend Payout %	0.00	0.00	0.00	3.46	5.36	40.65	40.30	37.15	69.11	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Reserves	151	218	242	296	359	451	506	584	707	765
Borrowings	0.00	0.00	0.00	0.00	12	12	8.63	7.21	4.59	36
Other Liabilities	247	193	214	261	330	306	337	389	362	712
Total Liabilities	403	415	461	562	706	775	857	985	1,078	1,518
Fixed Assets	97	87	75	75	72	81	74	69	67	64
CWIP	6.31	4.81	3.57	6.90	24	4.02	2.20	1.33	0.27	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	299	324	382	480	611	690	780	915	1,011	1,454
Total Assets	403	415	461	562	706	775	857	985	1,078	1,518

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	57	38	8.79	55	87	105	101	58	28	65
Cash from Investing Activity	-3.61	0.25	-9.36	4.28	-171	173	4.74	18	22	31
Cash from Financing Activity	-0.51	0.00	0.00	0.00	-6.36	-8.97	-9.46	-24	-44	-66
Net Cash Flow	53	38	-0.57	59	-90	269	96	52	5.23	31

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ABBOTINDIA	27900.00	59,278 Cr	39.28	14.78	1.70	37.62	48.38	26.50
GLAXO	2575.00	43,623 Cr	45.76	25.54	2.10	55.94	74.64	26.06
PFIZER	5034.00	22,933 Cr	32.45	5.96	3.29	18.36	24.12	18.22
ASTRAZEN	9137.50	22,811 Cr	98.68	28.55	0.35	28.93	37.48	12.33
SANOFICONR	4570.00	10,559 Cr	49.14	41.08	1.20	77.82	92.58	51.64
SANOFI	4204.00	9,666 Cr	25.45	11.23	2.78	42.11	52.41	25.64
PGHL	5663.25	9,422 Cr	30.71	15.20	2.20	49.51	65.17	34.30

Overview

Detailed Summary

APIL's recent launch of innovative drugs like Transtuzumab Deruxtecan for breast cancer marks its significant entry into advanced oncology treatment.

While regulatory interventions have influenced drug pricing, strategic responses like partnerships with Dr. Reddy's Laboratories and Sun Pharma enhanced APIL’s market access and portfolio reach.

APIL continues its R&D expansion in Bangalore, reinforcing its role within AstraZeneca’s global research network.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Multinational

Market Cap

22,811 Cr

Volatility

Low Risk

P/E Ratio

98.7

Industry P/E

41.4

PEG Ratio

4.2

P/B Ratio

28.6

52W High

10,653.05

52W Low

6,301.00

Sales CAGR

32.48%

28.67%

15.59%

10Y

13.03%

Profit CAGR

-28.34%

23.40%

9.89%

10Y

40.99%

ROE

TTM

28.93%

18.18%

17.49%

10Y

16.38%

ROCE

TTM

37.48%

24.02%

23.16%

10Y

22.37%